Cancer Stem Cell News
Cancer Stem Cell News
Cancer Stem Cell News is an online resource that curates the top research publications and reviews about cancer progenitor cells and cancer stem cells.
Subscribe|Follow Us On
From Smoke to Stemness: Mechanisms of Cancer Stem Cell Induction by Cigarette Smoke
[Biochimica Et Biophysica Acta-Reviews On Cancer] Beyond mutagenesis, cigarette smoke remodels cell state by promoting stem-like programs and enriching CSCs, a subpopulation with self-renewal capacity and therapy resistance that drives tumor heterogeneity, metastasis, and treatment failure.
MetroHealth Scientist Awarded $3.3 Million NIH Grant to Study How Breast Cancer Spreads
[MetroHealth] MetroHealth Research Institute scientist Dr. Khalid Sossey-Alaoui has been awarded a five-year, $3.3 million grant from the National Institutes of Health to lead research aimed at understanding and preventing the spread of breast cancer.
MAP2-Mediated Integrin Dysregulation Reprograms Cancer Cell Plasticity in Hepatocellular Carcinoma
[Nature Communications] Investigators explored the potential of repurposing an existing drug estramustine phosphate for targeting hepatocellular carcinoma (HCC) plasticity through inhibiting MAP2, a gene uniquely enriched in CD133+ ‘HCC’ stemness subset but not in CD133+ ‘normal’ regenerative cells.
Targeting the PRMT5-CBX8 Axis Overcomes Dual Barriers of CD8⁺ T Cell Exclusion and Tumor Stemness for Sensitizing TNBC to Anti-PD-1 Therapy
[Oncogene] Researchers unveiled a novel epigenetic pathway orchestrated by protein arginine methyltransferase 5 (PRMT5) that converges on the functional modulation of chromobox homolog 8 (CBX8) to synchronously governs CD8⁺ T cell exclusion and tumor stemness.
An Epitranscriptomic-Metabolic Axis from YTHDF1 to SQLE Drives Breast Cancer Stemness
[Communications Biology] Investigators identified a pivotal epitranscriptomic-metabolic axis implicated in breast CSC (BCSC) maintenance. Denetic depletion of either YTHDF1 or squalene epoxidase (SQLE) impairs core BCSC properties and reduces expression of cancer stem cell markers in vivo.
$3.3 Million NIH Grant Funds Upstate Research into New Immunotherapy for Leukemia
[SUNY Upstate Medical University] Immunologist Dr. Mobin Karimi has been awarded a $3.3 million grant to explore a new type of immunotherapy to treat acute myeloid leukemia. The grant comes from the National Cancer Institute of the National Institutes of Health.
Psoralidin Inhibits Stemness-Associated Characteristics in Cervical Cancer Cells via Modulation of Oct4/Sox2 Expression
[Naunyn-Schmiedebergs Archives of Pharmacology] Scientists explored the potential of psoralidin to target cervical cancer-CSCs. Molecular docking (MD) and MD simulation was conducted to analyze the interaction of psoralidin with core stemness markers Oct4, Sox2, and Nanog and stability of interaction, respectively.
H3K27M Drives OPC Stemness and Intrathecal Therapeutic Vulnerability in Brainstem Glioma Organoids
[Cell Stem Cell] Multi-omics and functional assays revealed that diffuse midline gliomas (DMGs) maintain oligodendrocyte precursor cell (OPC) stemness by dysregulating ACTIVIN signaling. To target stemness, researchers conducted an intrathecal drug screening and identified triple intrathecal therapy as a potent regimen against DMGs.
Targeting Tumor Heterogeneity Using an Injectable Gelatin Hydrogel for the Dual Elimination of Cancer Cells and Cancer Stem Cells
[Biomaterials Science] Investigators engineered an injectable in situ-forming gelatin hydrogel capable of the sustained, localized co-delivery of resveratrol and salinomycin, thereby simultaneously targeting both cancer cells and breast CSCs.
Rewiring Cellular Context As a Central Mechanism Governing Cancer Stem Cell Survival: Insights from ESC Comparisons
[Stem Cell Reviews and Reports] The authors advance the hypothesis that CSC persistence emerges not from any single factor, but from the integrative rewiring of signaling cascades, stress-responsive transcription factors, and core pluripotency networks within a survival-centric context, reinforced by dynamic chromatin remodeling.
Dr. Antoni Ribas Receives ESMO Lifetime Achievement Award for Contributions to Cancer Immunotherapy
[UCLA Health] Dr. Antoni Ribas, professor of medicine at the David Geffen School of Medicine at UCLA has received the 2026 ESMO Lifetime Achievement Award for his pioneering contributions to cancer immunotherapy and translational research.
AML1-ETO Hijacks a Distal Enhancer of NAT10 to Reprogram Glutathione Metabolism and Sustain Leukemia Stem Cell Stemness
[Proceedings of The National Academy of Sciences of The United States of America] Genetic ablation or pharmacological inhibition of NAT10 restricted the survival and self-renewal of LSCs in primary t(8;21) acute myeloid leukemia (AML) CD34+ cells, as well as in a retroviral AML1-ETO9a-driven t(8;21) AML mouse model.
Cancer Stem Cell News consolidates the most recent publications covering research areas such as the identification and isolation of cancer stem cells, their proliferation and differentiation characteristics, gene expression and regulatory pathways, and the development of anti-cancer therapies. We also include cancer stem cell jobs and events hosted by leading research organizations, societies, and institutes.
